VERONIKA KLOBOVES PREVODNIK

Prof. VERONIKA KLOBOVES PREVODNIK

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2011 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
VPVERONIKA KLOBOVES PREVODNIK
VERONIKA KLOBOVES PREVODNIK
JLJaka Lavrenčak
Jaka Lavrenčak
MHMateja Horvat
Mateja Horvat
BNBarbara Jezeršek Novaković
Barbara Jezeršek Novaković
In our recent study, we determined the cut-off value of CD20 expression at the level of 25 000 molecules of equivalent soluble fluorochrome (MESF) to be the predictor of response to rituximab containing treatment in patients with B-cell lymphomas. In 17.5% of patients, who had the level of CD20 expression below the cut-off value, the response to rituximab containing treatment was significantly worse than in the rest of the patients with the level of CD20 expression above the cut-off value. The proportion of patients with low CD20 expression who might not benefit from rituximab containing treatment was not necessarily representative. Therefore the aim of this study was to quantify the CD20 expression in a larger series of patients with B-cell lymphomas which might allow us to determine more reliably the proportion of patients with the CD20 expression below the cut-off.

1 April 2021 in Journal of Controlled Release
Verified
Journal Article
Open access
KVKatja Ursic Valentinuzzi
Katja Ursic Valentinuzzi
SKSpela Kos
Spela Kos
Urska KamensekUrska Kamensek
Urska Kamensek
MCMaja Cemazar
Maja Cemazar
VPveronika kloboves prevodnik
veronika kloboves prevodnik
Gregor SersaGregor Sersa
Gregor Sersa
Electrochemotherapy (ECT) exhibits high therapeutic effectiveness in the clinic, achieving up to 80% local tumor control but without a systemic (abscopal) effect. Therefore, we designed a combination therapy consisting of ECT via intratumoral application of bleomycin, oxaliplatin or cisplatin with peritumoral gene electrotransfer of a plasmid encoding interleukin-12 (p. t. IL-12 GET). Our hypothesis was that p. t. IL-12 GET potentiates the effect of ECT on local and systemic levels and that the potentiation varies depending on tumor immune status. Therefore, the combination therapy was tested in three immunologically different murine tumor models. In poorly immunogenic B16F10 melanoma, IL-12 potentiated the antitumor effect of ECT with biologically equivalent low doses of cisplatin, oxaliplatin or bleomycin. The most pronounced potentiation was observed after ECT using cisplatin, resulting in a complete response rate of 38% and an abscopal effect. Compared to B16F10 melanoma, better responsiveness to ECT was observed in more immunogenic 4 T1 mammary carcinoma and CT26 colorectal carcinoma. In both models, p. t. IL-12 GET did not significantly improve the therapeutic outcome of ECT using any of the chemotherapeutic drugs. Collectively, the effectiveness of the combination therapy depends on tumor immune status. ECT was more effective in more immunogenic tumors, but GET exhibited greater contribution in less immunogenic tumors. Thus, the selection of the therapy, namely, either ECT alone or combination therapy with p. t. IL-12, should be predominantly based on tumor immune status.

6 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MMMargarita Maurer-Granofszky
Margarita Maurer-Granofszky
ASAngela Schumich
Angela Schumich
BBBarbara Buldini
Barbara Buldini
GGGiuseppe Gaipa
Giuseppe Gaipa
JKJános Kappelmayer
János Kappelmayer
OIOn Behalf Of I-Bfm-Flow-Network
On Behalf Of I-Bfm-Flow-Network
Monitoring of minimal residual disease (MRD) by flow cytometry (FCM) is a powerful prognostic tool for predicting outcomes in acute lymphoblastic leukemia (ALL). To apply FCM-MRD in large, collaborative trials, dedicated laboratory staff must be educated to concordantly high levels of expertise and their performance quality should be continuously monitored. We sought to install a unique and comprehensive training and quality control (QC) program involving a large number of reference laboratories within the international Berlin-Frankfurt-Münster (I-BFM) consortium, in order to complement the standardization of the methodology with an educational component and persistent quality control measures. Our QC and quality assurance (QA) program is based on four major cornerstones: (i) a twinning maturation program, (ii) obligatory participation in external QA programs (spiked sample send around, United Kingdom National External Quality Assessment Service (UK NEQAS)), (iii) regular participation in list-mode-data (LMD) file ring trials (FCM data file send arounds), and (iv) surveys of independent data derived from trial results. We demonstrate that the training of laboratories using experienced twinning partners, along with continuous educational feedback significantly improves the performance of laboratories in detecting and quantifying MRD in pediatric ALL patients. Overall, our extensive education and quality control program improved inter-laboratory concordance rates of FCM-MRD assessments and ultimately led to a very high conformity of risk estimates in independent patient cohorts.

29 April 2002 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
VPVERONIKA KLOBOVES PREVODNIK
VERONIKA KLOBOVES PREVODNIK
JJJanez Jazbec
Janez Jazbec
MUMarija Us‐Krašovec
Marija Us‐Krašovec
JLJanez Lamovec
Janez Lamovec

27 October 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MUMojca Urbancic
Mojca Urbancic
VPVERONIKA KLOBOVES PREVODNIK
VERONIKA KLOBOVES PREVODNIK
DPDaniel Petrovič
Daniel Petrovič
MPMojca Globočnik Petrovič
Mojca Globočnik Petrovič
The purpose of this study was to investigate inflammatory cells in vitreous from patients with proliferative diabetic retinopathy (PDR) using flow cytometric analysis. Twenty-eight patients with PDR requiring vitrectomy because of macular traction or tractional retinal detachment were enrolled in the study (n=28), and 6 patients with macular hole (MH) formed the control group. Samples of vitreous and peripheral venous blood were obtained at the beginning of vitrectomy. T lymphocytes were found in vitreous from patients with PDR, and CD4/CD8 ratio was higher in vitreous (median 4.3) compared to blood (median 1.9;P=0.003). No B lymphocytes were detected in vitreous. The percentage of histiocytes/macrophages was significantly higher in vitreous (median 62.1) in comparison with blood (median 5.5;P<0.0001). No lymphocytes were detected in vitreous of the control group. There were more T lymphocytes in vitreous from patients with active PDR. No association between cells in the vitreous and visual acuity improvement after surgery was found. In conclusion, T lymphocytes are found in vitreous from patients with PDR and reflect the activity of PDR but do not seem to predict visual prognosis. Higher CD4/CD8 ratio in vitreous compared to blood from patients with PDR is consistent with local inflammatory response in PDR.

2 August 2005 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
VPVERONIKA KLOBOVES PREVODNIK
VERONIKA KLOBOVES PREVODNIK
MUMarija Us‐Krašovec
Marija Us‐Krašovec
NGN. Gale
N. Gale
JLJanez Lamovec
Janez Lamovec